Clinical Trial Detail

NCT ID NCT03724968
Title Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Elizabeth Davis
Indications

melanoma

Therapies

Nivolumab + Relatlimab

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.